New drug for CMV after transplants

The European Medicines Agency has recommended a new medicine that can prevent cytomegalovirus (CMV) reactivation and disease in patients who have received an allogeneic stem cell transplant. The medicine, Prevymis (letermovir), was developed by Merck & Co Inc.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom